Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Genentech’s Phase II Trial Promising for Pertuzumab Combo in Breast Cancer

Drug Industry Daily

Dec. 14, 2010 | Vol. 9 No. 241

Genentech’s Phase II Trial Promising for Pertuzumab Combo in Breast Cancer

Genentech has moved one step further in its bid to file for a first-line indication for a combination of Herceptin plus pertuzumab as an adjunct to chemotherapy in HER2-positive breast cancer.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Analyst: Study Shows Some Potential for Vertex’s CF Combo Treatment Amgen: Denosumab Superior to Zometa in Advanced Breast Cancer Patients FDA Lifts Partial Clinical Hold on Genmab Cancer Drug FDA Says Genta May Resume Clinical Trial of Tesetaxel

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.